Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | ME2 | P23368 | 1/20 | 0.52 |
| ▸ | ME1 | P48163 | 1/20 | 0.52 |
| ▸ | ME3 | Q16798 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14115766 | 0.84 | POLB (0.58) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL20386535 | 0.84 | SMN1; SMN2 (0.59) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL13701287 | 0.82 | L3MBTL1 (0.75) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL14393336 | 0.82 | POLB (0.56) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL27559589 | 0.81 | L3MBTL1 (0.73) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL14115762 | 0.81 | POLB (0.61) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL3501319 | 0.79 | HSD11B1 (0.61) | POLBALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL23573298 | 0.79 | PKM (0.63) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL31381166 | 0.78 | ALDH1A1 (0.67) | POLBSMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL14495101 | 0.78 | PKM (0.59) | POLBSMN1; SMN2ALDH1A1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | POLB 4658/4885SMN1; SMN2 4779/4885ALDH1A1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.